
China Pharmaceutical Innovation Boom: Biotech Licensing Deals Top $60 Billion in Q1 2026
Key Points: China’s domestic biotechnology and pharmaceutical sectors are experiencing an unprecedented boom, driven by aggressive regulatory reforms, rapid market approvals, and record-breaking international partnership































